ALMKT:EPA
Mauna Kea Technologies SA
0,092 €
0,00%
(0,00) 1D
13. stu, 17:35:01 GMT+1 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za ALMKT...
Otvori
0,09 €
Najviša
0,10 €
Najniža
0,09 €
Trž. kap.
18,14 mil.
Prosj. kol.
541,14 tis.
Količina
75,16 tis.
P/E omjer
0,79
52-tjed. najviša
0,23 €
52-tjed. najniža
0,07 €
EPS
0,12 €
Dionice u optjecaju
195,26 mil.
Broj djelatnika
56
Otvori
0,09 €
Najviša
0,10 €
Najniža
0,09 €
Trž. kap.
18,14 mil.
Prosj. kol.
541,14 tis.
Količina
75,16 tis.
P/E omjer
0,79
52-tjed. najviša
0,23 €
52-tjed. najniža
0,07 €
EPS
0,12 €
Dionice u optjecaju
195,26 mil.
Broj djelatnika
56
Vijesti
Iz web-izvora i od partnera za vijesti
TradingView
·
prije 5 sati
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
24/7 Wall St.
·
prije 1 sat
He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076
Bloomberg.com
·
prije 10 sati
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Traders Union
·
prije 5 sati
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profil
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Mauna Kea Technologies SA – informacije
Glavni izvršni direktorSacha Loiseau
Zaposlenici56
Osnovano2000
Sjedište-
SektorHealth Care
Djelatnost-
Web-lokacijamaunakeatech.com